
Eli Lilly’s retatrutide, a GIP/GLP-1/glucagon triple agonist, met Phase 3 endpoints, delivering 28.3% weight loss over 80 weeks in TRIUMPH-1.
#EliLilly #Retatrutide #GLP1 #GIP #Glucagon #ObesityTreatment #Phase3 #TRIUMPH1 #WeightLossDrugs

English
BIS Research
5.7K posts

@BISResearch
Your search for the latest #MarketInsights on deep technologies ends with us. Get answers to all your business questions in one place.







































